The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-one infections whose virus is at present suppressed (Administration of high doses of tenofovir continues to be reported to provide bone toxicity reported as osteomalacia and reduced bone mineral density and to generate some diploma of renal toxicit… Read More